On November 8, 2024 Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, reported the "Preclinical Development of 7MW4811, an Mtoxin (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15th World ADC San Diego, held from Nov. 4 to 7, 2024 (Press release, Mabwell Biotech, NOV 8, 2024, View Source [SID1234648043]). The post revealed compelling data from the studies on the efficacy of 7MW4811 in treating solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

7MW4811 is developed with Mabwell’s next-generation ADC technology (IDDC) platform, and has demonstrated encouraging anti-tumor effects across a range of solid tumors, including lung, colorectal, pancreatic and gastric cancers. Notably, it has shown promising therapeutic potentials in gastrointestinal tumors.

IDDC is a clinically validated site-specific conjugation technology that has been instrumental in the development of ADCs with good homogeneity, efficacy, and safety profiles. Coupled with the novel payload Mtoxin (MF6), these ADCs have been furthered optimized, exhibiting enhanced pharmacodynamics, bystander killing efficacy, and anti-multidrug resistance capabilities.